In this proposal, we investigate the feasibility of performing compartmental analysis (CA) of 18FM1S0 dynamic PET (dynPET) images in NSCLC patients undergoing neoadjuvant chemotherapy. The 5-yr survival of stage IA NSCLC patients treated with surgery alone is 73%, falling to 58% and 13% for stages IB and IIIA respectively for patients who are surgically staged. Thus, it is necessary to identify prognostic factors determining patient outcome, which will ultimately lead to new treatment regimens. Tumor hypoxia is an independent predictor of poor prognosis in several types of cancer, including NSCLC. Achieving successful hypoxia imaging for prognosis in lung cancer is of greater relevance than for other cancers (e.g. HNC) because the local control in NSCLC is comparatively low. 18FM1S0 PET has been shown to correlate with hypoxia in NSCLC, and that the optimum method to quantitate hypoxia using 18FMIS0 is via compartment analysis of the corresponding dynPET images. However, CA is implausible with PET images of lung due to breathing. We propose a novel technique for motion-correction of 18FMIS0 dynPET images of lung to make CA possible. Our group at MSKCC was the first to establish the methodology for both respiratory gated and Breath-Hold (BH) PET/CT. We will quantitate the uncertainties in CA due to target motion using Monte Carlo simulations of oscillating hypoxic targets in normoxic lung background. We will then demonstrate our method's feasibility in clinical settings. We shall acquire patient clinical 18FMIS0 dynPET images in Free- Breathing (FB) in list mode (LM). We will select end-expiration (EE) events from the LM data using the patient's respiratory signal to produce a BH-like PET data set. Kinetic parameters will be determined from CA of both FB and BH dynPET images and then compared to assess differences due to target motion. We will also examine the feasibility of CA of 18FMIS0 BH dynPET of NSCLC in patients, and will assess the reproducibility of CA in repeat 18FMIS0 dynPET. Finally, we will investigate whether BH 18FMIS0 PET results in an improved correlation with treatment outcome. If this is the case, this approach may set the stage for future studies in which hypoxia imaging findings will be used to modify treatment.
BH dynamic PET/CT should improve the prognostic value of 18F-FMIS0, and pave the way for future studies targeting hypoxic sub-regions with the ultimate goal to improve the treatment outcome and overall survival of patients with NSCLC.
|Nehmeh, Sadek A; Schwartz, Jazmin; Grkovski, Milan et al. (2018) Inter-operator variability in compartmental kinetic analysis of 18F-fluoromisonidazole dynamic PET. Clin Imaging 49:121-127|
|Beichel, Reinhard R; Smith, Brian J; Bauer, Christian et al. (2017) Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data. Med Phys 44:479-496|
|Grkovski, Milan; Lee, Nancy Y; Schöder, Heiko et al. (2017) Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. Eur J Nucl Med Mol Imaging 44:1682-1691|
|Grkovski, Milan; Schwartz, Jazmin; Gönen, Mithat et al. (2016) Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. J Nucl Med 57:334-41|
|Schwartz, J; Humm, J L; Gonen, M et al. (2011) Repeatability of SUV measurements in serial PET. Med Phys 38:2629-38|